Page 33 - Layout 1

COVID-19 UPDATE

For more information, please visit www.no-
covidstudy.com.

If patients meet the following criteria,
then they will qualify to participate in the
study:
1. Hispanic or African American
2. Aged 50-85
3. Diagnosed with COVID in the past 72
hours
4. Have at least one comorbidity such as hy-
pertension, diabetes, heart disease, kidney
disease, obesity or a smoker.

References:
1. Shi, S., et al., Association of Cardiac Injury
With Mortality in Hospitalized Patients
With COVID-19 in Wuhan, China. JAMA
Cardiol, 2020.
2. Yancy, C.W., COVID-19 and African
Americans. JAMA, 2020.
Restoring nitric oxide through drug therapy is reported to improve oxy-
7,8
genation, an action needed as the COVID-19 disease progresses and 3. Carnethon, M.R., et al., Cardiovascular Health in African Amer-
icans: A Scientific Statement From the American Heart Associa-
acute respiratory disease syndrome (ARDS) develops. NO decreases
9
the propensity of blood to clot, a problem leading to multi-system dam- tion. Circulation, 2017. 136(21): p. e393-e423.
4. Connors, J.M. and J.H. Levy, COVID-19 and its implications for
age in patients severely ill with the COVID-19 virus.
thrombosis and anticoagulation. Blood, 2020.
All these factors: decreased oxygenation, low NO levels in Hispanic
5. Varga, Z., et al., Endothelial cell infection and endotheliitis in
and Africans American patients, decreased oxygenation in severely ill
COVID-19. Lancet, 2020. 395(10234): p. 1417-1418.
COVID-19 patients, increased clotting and increased inflammation,
6. Bonetti, P.O., L.O. Lerman, and A. Lerman, Endothelial dysfunc-
leads one to hypothesize that increasing NO levels in patients with
tion: a marker of atherosclerotic risk. Arterioscler Thromb Vasc
COVID-19 would have a salutatory benefit. A Texas-based biotech-
Biol, 2003. 23(2): p. 168-75.
nology company, Nitric Oxide Innovations, is conducting an FDA-
7. Allen, B.W., J.S. Stamler, and C.A. Piantadosi, Hemoglobin, nitric
approved Phase 3 clinical trial for a novel nitric oxide releasing drug
oxide and molecular mechanisms of hypoxic vasodilation. Trends
therapy for Hispanic and African American patients aged 50-85 di-
Mol Med, 2009. 15(10): p. 452-60.
agnosed with COVID in the last 72 hours. The clinical trial aims to
8. Zhang, R., et al., Hemoglobin betaCys93 is essential for cardio-
investigate if restoring nitric oxide can prevent progression of disease
vascular function and integrated response to hypoxia. Proc Natl
and hospitalization, reduced need for ventilation and decrease death.
Acad Sci U S A, 2015. 112(20): p. 6425-30.
Early data from the clinical study reveals that nitric oxide can improve
9. Radomski, M.W., R.M. Palmer, and S. Moncada, The anti-aggregat-
oxygenation in patients within five minutes of taking the drug. His-
ing properties of vascular endothelium: interactions between prosta-
panics and African-Americans are known to be nitric oxide deficient
cyclin and nitric oxide. Br J Pharmacol, 1987. 92(3): p. 639-46.
and respond favorably to nitric oxide-based therapies. Patients are

needed in the clinical study. Subjects will be randomly assigned to re-
Nathan S. Bryan, PhD is the Founder and CEO of Nitric
ceive either an NO active drug lozenge or a placebo for 30 days. The
Oxide Innovations, LLC. Nitric Oxide Innovations, LLC is
primary outcome measures rates of hospitalization, admission into the
a Gold Circle of Friends Sponsor of the BCMS. For more in-
intensive care unit and death in patients on the drug compared to the
formation, you can contact him at nathan@pneumanitricoxide.com.
placebo. A secondary endpoint will be the fractional oxygen saturation
of patients receiving the drug compared to those on the placebo.
Visit us at www.bcms.org 33